This article is more than 5 years old. Information may no longer be current.

Lumenis receives U.S. OK for retinal laser

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

YOKNEAM, Israel — An infrared diode photocoagulator laser received U.S. regulatory approval for the treatment of retinal diseases, according to a press release from the laser manufacturer, based here.

The Food and Drug Administration granted Lumenis approval for its Novus TTx 810 Nanometer Infrared Diode Photocoagulator. The Novus TTx combines the power of an 810-nm infrared laser “with Lumenis’ exclusive and highly-adaptable user interface, giving ophthalmologists an advanced device to treat even the most complicated retinal conditions,” said Avner Raz, president and chief executive officer, in a press release issued by the company.